Active substance: Trilostane 30 mg
This product is no longer in stock
Treatment of hyperadrenocorticism (Cushing's disease and syndrome) pituitary or adrenal origin in dogs.
Do not use in animals with primary liver disease and / or kidney failure. Do not use in animals with weight
kg.No divide less than 3 capsules.
In dogs treated with trilostane, there has been lethargy, vomiting, diarrhea and anorexia in the absence of evidence
hypoadrenocorticism. In dogs treated with Vetoryl have referred isolated cases of adrenal necrosis, which can
hypoadrenocorticism cause. May be unmasked subclinical renal dysfunction after treatment with the
product.The may unmask arthritis treatment due to a reduction in the levels of endogenous corticosteroids.
Have referenced a small number of cases of sudden death during adverse effects tratamiento.Otros
mild and infrequent presentation include ataxia, hypersalivation, bloating, muscle tremors and
DOSAGE AND DOSAGE:
It is administered orally, once daily, with food. In clinical studies, the initial dose was effective half
6 mg / kg once daily. The dose should be adjusted according to individual response as determined by the
monitoring the patient. The following are recommended starting doses:
Body weight starting dose Dosage
<3 kg and <10 mg 3.10 Kg 30 mg / Kg
<10 kg and <20 kg 60 mg 3-6 mg / Kg
<20 kg and <40 mg 3-6 Kg 120 mg / Kg
<40 kg 120-240 mg 3-6 mg / Kg
ADVICE ON CORRECT ADMINISTRATION:
A small number of animals may require substantially higher doses than 10 mg / kg / day. In these situations,
made appropriate additional monitoring. Specimens for biochemical analysis (including
electrolytes) and performed ACTH stimulation tests (at 4-6 hours after administration) before starting the
treatment, after 10 days, 4 weeks and 12 weeks of this and later, every three months, both after
initial diagnosis and following dose adjustments.
Do not store above 25 ° C.
Keep out of the reach and sight of children. Do not use after the expiration date shown on
SPECIAL PRECAUTIONS FOR USE:
Since most cases of hyperadrenocorticism are diagnosed in dogs aged between 10 and 15 years,
concomitant presence of other disease processes is often. In particular, it is important to rule initially
existence of primary liver disease and renal failure, as the product is contraindicated in these cases.
During treatment should be closely monitored. Special attention should be paid to the enzymes
liver, electrolytes, urea and creatinine. The concomitant presence of diabetes mellitus and hyperadrenocorticism
requires specific monitoring. If a dog has been previously treated with mitotane, adrenal function is
The practical experience suggests that it should be a gap of one month between the end of the administration of
mitotane and trilostane treatment initiation. We recommend close monitoring of adrenal function, and
these dogs may be more sensitive to the effects of trilostane.
Use during pregnancy and lactation:
Do not use in dogs during pregnancy or lactation or in animals intended for breeding.
DRUG INTERACTIONS AND OTHER FORMS OF INTERACTION:
Should be considered the risk of hyperkalemia when used with trilostane sparing diuretics
potassium or inhibitory drugs angiotensin converting enzyme.
No customer reviews for the moment.